‘Global Pharma Cmos Market Worth $105.3bn In 2021’ Says Visiongain Report

15 August 2018
Pharma

Visiongain’s new report Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027 North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing report indicates that the Global Pharma CMOs Market will see $105.3bn in spending in 2021.
The global pharmaceutical contract manufacturing
market was valued at $76.6bn in 2016 and is expected to grow at a CAGR of 6.6% in the first half of the forecast period. Between 2011 and 2016, the top 5 emerging market CMOs grew at a CAGR of 13.6%, whereas the leading developed market CMOs grew at a CAGR of 1.7% over the same period.

The lead analyst of the report said: “Market drivers will stem from the increased demand for outsourcing in developed markets, particularly from big pharma companies. These companies will increasingly look to form long-term strategic partnerships with global CMOs, demanding services from pre-clinical formulation development through to commercial supply. Big pharma companies are looking to reduce fixed cost and simplify their outsourced service supplier networks, forming strategic partnerships with just a few service providers. However, demand for specialist services, as well as the need for local, small-scale manufacturing from pharmaceutical start-ups, will drive growth for smaller, specialist CMOs.

While growth is forecast for this market throughout the period 2017-2027, restraining factors exist. The highly-fragmented nature of the market means that it is very competitive and not all companies are likely to prosper or survive. Those that have expanded too quickly, investing in increased capacity, may not be able to find the demand to cover investments. Factors impacting overcapacity will include the development of targeted therapies and orphan drugs, which have smaller target patient populations and hence require smaller quantities of drug to be manufactured.”

The 311-page report contains 184 tables and 111 figures that add visual analysis in order to explain the developing trends within the Global Pharma CMOs market.

Visiongain provides revenue forecasts for the period 2017-2027 for the global CMOs market as well as the leading segments of that market: API, FDF and Other Services

Furthermore, this report profiles 30 leading CMOs in North America, Europe, Japan, China and India.

The content of each profile differs, depending on the organisation. In general, a profile gives the following information: Overview of the company’s contract manufacturing services and operations, analysis of recent financial performance, activities, acquisitions, production capacity, deals, new service offerings and collaborations, SWOT analysis, forecasting of pharmaceutical manufacturing revenue to 2027, as well as projected operating profit and margin for some companies.

The Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027 North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing report will be of value to anyone who wants to better understand the Pharma CMOs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Pharma CMOs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever